drugset / Trial / NCT07014826
A Trial of HRS-5965 Capsule in Primary IgA Nephropathy
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This multicenter, randomized, double-blind, parallel, placebo-controlled study is being conducted to evaluate the efficacy, and safety of HRS-5965 capsule for primary IgA nephropathy.
Timeline
- Start
- 2025-06-04
- Primary completion
- 2027-10
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HRS-5965 | Small molecule | — | — |